The US FDA has approved obecabtagene autoleucel for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). Obecabtagene Autoleucel is a CD19-directed genetically modified autologous T-cell immunotherapy.
Clinical evidence In a clinical trial conducted on 112 patients, obecabtagene autoleucel achieved a 63% overall complete remission rate with a median remission duration of 14.1 months. Dosage and administration Available as a cell suspension IV infusion Warnings and precautions Prolonged cytopenia Infections Hypogammaglobulinemia Hemophagocytic lymphohistiocytosis/macrophage activation syndrome Hypersensitivity reactions Secondary malignancies Adverse reactions – Infections, cytokine release syndrome, musculoskeletal pain, fever, nausea, diarrhea, bacterial infectious disorders, febrile neutropenia, hypotension, fatigue, pain,…
